



Carl D'Ruiz, MPH

Senior Manager, North America Beauty & Care Business Development

Carl D'Ruiz is a prominent figure in the sunscreen industry, serving as the Senior Manager of the Beauty and Care Business North America for dsm-firmenich, a global leader in nutrition, health, and beauty innovation. With over three decades of expertise in regulatory affairs, scientific strategy, advocacy, and business development, Carl has established himself as a thought leader in advancing sunscreen technology and regulatory reform, particularly in the United States.

Carl's impactful career reflects a deep commitment to public health, innovation, and industry leadership. He has spearheaded DSM's FDA OMOR submission for PARSOL® Shield (Bemotrizinol), advanced sunscreen standards in the U.S., and led advocacy campaigns for safer sun care and sustainability. A skilled strategist, Carl delivers tailored solutions that accelerate product commercialization and drive growth.

As the Head of Science, Advocacy, and Business Development at dsm-firmenich Beauty Care North America, Carl has established himself as a visionary thought leader in sunscreens, photoprotection, and public health. His unparalleled expertise lies in seamlessly navigating the complex regulatory, scientific, and business landscapes, consistently spearheading groundbreaking innovations that set new industry standards.

Carl holds a master's degree in public health from the Yale School of Public Health, a bachelor's degree in Political Science from Fordham University, and executive business certifications from The Darden and Wharton Business Schools. His commitment to advancing the field is further evidenced by his full membership in the Society of Toxicology, the Society of Cosmetic Chemists Scientific Affairs Committee, and his role on the Board of the Photodermatology Society. Through these prestigious positions, he continues to shape industry standards and contribute to public health advancements on a global scale. These efforts help public health and prevent the morbidity and mortality associated with skin cancer due to overexposure to the sun.

Carl's work is not just about business success; it's about making a lasting impact on public health and safety. His dedication to innovation, coupled with his deep regulatory and scientific acumen, has solidified his reputation as a trusted advisor and thought leader in the industry. He has previously presented at the Sunscreen Symposium, where his insights continue to shape the future of sun protection and skincare.

Carl also served as the former Chair of the Personal Care Products Council's Sunscreen Symposium, where he defended the safety of existing OTC sunscreen drug active ingredients. Additionally, he is actively involved in supporting the Skin Cancer Foundation's cancer detection and prevention programs.

Carl has been instrumental in pushing for updates to the U.S. sunscreen approval process. Through his leadership at dsm-firmenich, he has spearheaded efforts to gain FDA approval for Bemotrizinol (PARSOL® Shield), a broad-spectrum UV filter widely used globally but not yet approved in the U.S. Notably, PARSOL® Shield is the first and only new sunscreen active ingredient to be sponsored for FDA approval under the FDA's new OTC Monograph Order (OMOR) pathway created by the CARES Act of 2021. As chair of the PCPC Sunscreen Consortium, Carl collaborated closely with the FDA to defend the safety of UV filters and advocated for modernized non-animal testing approaches. These efforts aim to review the safety of existing active ingredients under the FDA's OTC Sunscreen Monograph and introduce new ingredients through the OTC Monograph User Fee Act (OMUFA) pathway. His work emphasizes streamlining regulatory processes to bring innovative, effective sun care products to the U.S. market, addressing a 25-year gap in new sunscreen active approvals.

His expertise has been widely recognized in the media, including NBC, CBS, CosmeticsDesign, and NPR, among others, highlighting the public health implications of delayed approvals, such as increased skin cancer risks, and advocating for faster integration of proven technologies like Bemotrizinol. Through his leadership, Carl continues to shape the future of sun care, blending scientific rigor with a passion for consumer safety and innovation.